+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cyramza

  • ID: 4462148
  • Drug Pipelines
  • 66 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
Note: Product cover images may vary from those shown
2 of 2

OVERVIEW
Drug Overview
Product Profiles
Cyramza : Non-small cell lung cancer (NSCLC)
Cyramza : Gastric cancer
Cyramza : Colorectal cancer (CRC)
Cyramza : Hepatocellular carcinoma (HCC)
Cyramza

LIST OF FIGURES
Figure 74: The authors drug assessment summary for Vargatef in non-small cell lung cancer
Figure 78: The authors drug assessment summary for Xalkori in non-small cell lung cancer
Figure 79: The authors drug assessment summary for Xalkori in non-small cell lung cancer
Figure 80: Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 81: Zykadia for non-small cell lung cancer – SWOT analysis
Figure 7: Cyramza for colorectal cancer – SWOT analysis
Figure 8: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 83: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 84: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 84: Capmatinib for non-small cell lung cancer – SWOT analysis
Figure 12: The authors drug assessment summary of Cyramza for hepatocellular carcinoma
Figure 85: The authors drug assessment summary for capmatinib in non-small cell lung cancer
Figure 87: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 88: Cemiplimab for non-small cell lung cancer – SWOT analysis

LIST OF TABLES
Table 1: Cyramza drug profile
Table 2: Cyramza pivotal trial data in non-small cell lung cancer
Table 3: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Table 100: Vargatef patient numbers for NSCLC across the five major EU markets, by country, 2017–26
Table 5: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Cyramza drug profile
Table 7: Cyramza pivotal trial data in gastric cancer
Table 8: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 10: Cyramza drug profile
Table 11: Cyramza Phase III data in colorectal cancer
Table 12: Cyramza Phase I trials in colorectal cancer
Table 13: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 15: Cyramza drug profile
Table 107: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 17: Cyramza Phase III trial in HCC
Table 18: Cyramza Phase II data in HCC
Table 19: Cyramza drug profile
Table 20: Cyramza pivotal trial data in gastric cancer

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll